🎉 Health Canada Provides a No Objection Letter for ATMA’s N500 Phase II Clinical Trial Application

CALGARY, Jan. 28, 2021 – ATMA Journey Centers Inc. (“ATMA”), an Alberta-based company focused on delivering innovative psychedelic-assisted therapies internationally, is pleased to announce the appointment of Dr. Ravinder (Ravi) Bains, MD, as Chief Medical Officer (“CMO”). In conjunction with ATMA, Dr. Bains was the first psychiatrist in Canada to conduct legal psychedelic-assisted therapy using psilocybin at a private facility, and he will be leading the medical team and protocols utilized at ATMA Journey Centers in Canada.

David Harder, co-CEO of ATMA, said: “We’re thrilled to have Dr. Bains join the ATMA team at such a significant moment in time. Not only is Dr. Bains respected and accomplished in the field of psychiatry, but he also has the tremendous compassion and belief in psychedelic medicine necessary to allow ATMA to deliver services with world-class medical expertise and guidance.”

Dr. Bains has been a practicing psychiatrist and psychotherapist for 15 years and has focused his career on offering patients innovative and wholistic ways of improving their mental health.

Dr. Bains stated, “I believe that the remarkable potential of psychedelic medicine places us on the threshold of a mental health revolution. The emergent data over the past few years is beyond compelling, and I am pleased that my role at ATMA will allow me to work with one of the pioneering organizations in Canada with the vision and resource to translate science into genuine healing and transformation.”

Giving deference to the ongoing place of traditional pharmaceuticals in psychiatric practice, Dr. Bains envisions psychedelic-assisted therapy having the potential to revolutionize how we define and treat mental health issues.

Contrasting the decades long trend towards ever increasing rates of psychotropic prescribing with paradoxically increasing rates of chronic mental health disorders, addictions, disability and even suicide, Dr. Bains hopes the impending psychedelic revolution will finally “help bridge the yawning gap” between treatment and outcome. “It’s difficult to look at the data and not question the effectiveness of conventional approaches”, added Dr. Bains. 

“I have not seen much evidence in my 15 years of practice to support the historical contention that mental health issues are primarily a result of genetic disorders or chemical imbalances; rather, my experience is that mental health issues are more often understandable as being consequence of early adverse life events, ongoing life stressors, social determinants of health, and even existential issues, with regards to which traditional psychiatric treatments typically fall short.” 

“Most therapies in use today – aside from the psychotherapies – are suppressive in nature, in effect blunting emotional and anxiety pathways. While this model can be helpful or even life-saving, it’s not a model of healing, wellness or wholeness. Compounding the problem is that traditional pharmaceuticals, while of limited efficacy, are also far from benign, typically coming with an array of unpleasant or even dangerous side effects. Too many patients struggle to find relief in the long run.” 

In Dr. Bain’s view, “Psychedelic assisted therapies are expressive rather than suppressive, providing an opportunity to move beyond simply palliation to helping patients work through traumatic material and move towards genuine transformation. They also routinely transcend the traditional bio-psycho-social model of mental health and bring to the fore the critical element of spirit in the healing process.” 

Concluded Dr. Bains, “it’s important that we acknowledge the remarkable body of science around psychedelics; however, it’s the responsible and effective implementation of these powerful new technologies that is now the task at hand, and it’s here that ATMA is poised to be a true leader in the field.” 

Added Harder from ATMA: “Canada already faced a serious mental health crisis before COVID-19, but now it is a pressing and urgent issue that needs to be addressed. As a result, next week we will be submitting a Collective Application to Health Canada for a Section 56 Exemption on behalf of hundreds of Canadians that are struggling with serious and debilitating mental health conditions that simply cannot wait for help.” 

In the past year, Health Canada has approved approximately 25 applications from Canadians seeking an exemption to the current laws that prohibit the use of psychedelics in Canada. ATMA was the first private company in Canada to conduct legal psychedelic-assisted therapy with psilocybin, one of the active hallucinogens found in “magic mushrooms”. 

AS CMO, one of Dr. Bain’s first priorities will be providing the medical oversight and review of ATMA’s Collective Application, and to lead the treatment and protocols for ATMA’s growing team of mental health professionals. 

According to Harder, “Health Canada has demonstrated global leadership in their recognition and advancement of psychedelic-assisted therapy as a tool in the mental health battle Canadians are facing. The crisis we face is daunting, yet we’re prepared to meet the challenge because of talented team members like Dr. Bains who are committed to being part of the change.”

More News and Media:

Health Canada Provides a No Objection Letter for ATMA’s N500 Phase II Clinical Trial Application, Paving the Way for the Largest Psilocybin Trial to Date

ATMA’s N500 Phase II Clinical Trial will assess psilocybin efficacy in frontline healthcare professionals suffering from COVID-19-related mental wellness challenges. CALGARY, AB, Sept. 14, 2022 /CNW/ – ATMA Journey Centers Inc. (“ATMA”), an Alberta-based company focused on the international delivery of innovative psychedelic-assisted therapy solutions, announced today that it has received approval from Health Canada to move forward with its

Psychedelic Breakthrough

Breakthroughs in the Therapy Room – Hope for Treatment Resistant Mental Illness?

By Rachel Dundas, Registered Psychologist Certified Trauma Practitioner What does it mean to be an effective therapist? Surely, most new graduates are entering the therapy profession with energy, enthusiasm, and aspirations to support and empower their clientele. Intentions, however, do not always translate to therapeutic effectiveness. Does being an effective therapist mean you have a

ATMA Journey Centers observes positive outcomes from a Phase I clinical trial of psilocybin in healthy participants

Fourteen healthy subjects completed an experiential session after receiving 25 mg psilocybin  – Results of this phase I study will inform the design of Phase II study in frontline healthcare workers, examining the efficacy of psilocybin for Covid-related stress. Calgary, September 7, 2022 — ATMA Journey Centers (the “Company”), a company providing therapist training and support, has

Thank You Letter

Dear mental healthcare professionals, A deep heart-felt thank you is warranted to you for bearing the weight of the current mental health crisis, especially during these last tough couple of years. I have heard from many of your peers regarding the increased pressure, overburdening workloads, and feelings of burnout that have become an all too frequent occurrence.

Breaking Through the Stigma

By David Harder, ATMA co-founder and co-CEO I met with a gentleman – a pastor of sorts – from my former religious life. We sat down to enjoy a pint and a burger at a local watering hole. It had been many years since we had last spoken, simply due to the chaos of life,

How To Change Your Mind

Upon the release of his book How to Change Your Mind, Michael Pollan sparked a major shift in the mindset of numerous therapists and medical professionals, as well as the general public. At the time of its publication in the spring of 2019, discussions surrounding psychedelics were happening, but in small, hushed groups of underground

Clinical Trials and Psychedelics

Clinical trials are the standard way to evaluate the safety and efficacy of new drugs (including psychedelic drugs) for medical use. Clinical trials also serve to test novel treatment options, explore ways to improve quality of life for people living with illnesses or diseases, and assess whether a new drug or treatment has fewer side

Psilocybin-assisted Therapy: The Safe and Effective Alternative

Psilocybin-assisted therapy is becoming an increasingly widespread treatment for various mental health conditions. However, many healthcare professionals may be hesitant to use this type of treatment with their patients because of the misconception that psychedelics are dangerous and unsafe. This blog post will share evidence of the safety of psilocybin as an effective treatment option

Scroll to Top